While ResMed has maintained its dominance in the sleep apnoea market, analysts said the return of Dutch rival Philips to the US market after a product recall was a potential disruptor.

The renowned medical device company has a market capitalization of $35.10 billion. RMD has an earnings yield of 14.8%, outpacing the industry’s 14.4%. The company’s earnings surpassed estimates in ...

Learn More ResMed Inc (ASX: RMD) shares have extended gains this month, closing at fresh 52-week highs of $39.07 apiece on Monday. They have since retreated to $37.72 at the time of writing after ...

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem ...

ResMed Inc (NYSE:RMD) reports a robust 11% increase in net revenue year-over-year. Significant growth in Sleep and Breathing Health segment, showcasing an 11% rise in sales. Strong gross margin ...

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment. Shares of the ...

Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at https://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD ...